He Diagnosis Is Rare Up To 50 Of People With Uveal Melanoma Will Eventually Develop Metastatic Disease Unresectable Or Typically Hasa Poor Prognosis And Had No Approved Treatment Until Kimmtrak About Isa Novel Bispecific Protein Comprised Ofa Solublet Cell Receptor Fused An Anti Cd3 Immune Effector Function Specifically Targets Gp100 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval in the United States and the European Union PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the approval of KIMMTRAK(tebentafusp) by Health Canada and Therapeutics Goods Administration (TGA) for the treatment of unresectable or metastatic uveal melanoma (mUM), a rare and aggressive form of melanoma that affects the eye. KIMMTRAK was developed by Immunocore Holdings plc ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. The approval will enable Medison to commercia ....

United States , New Zealand , United Kingdom , Immunocore Imm , Marcus Butler , Dara Willis , Mark Moyer , Victor Papamoniodis , Medison Pharma , Meir Jakobsohn , Therapeutics Goods Administration , Tumor Immunotherapy Program , Gage Communications , Vp International Markets At Medison , European Union , Corporate Communications , Immunocore Holdings , Health Canada , Head Of Regulatory Affairs At Immunocore , Central Eastern Europe , Regulatory Affairs , Project Orbis , Medical Oncologist , Skin Medical Oncology Site Lead , Princess Margaret Cancer Centre , Hazard Ratio ,